Because of the risk of cytokine release syndrome (CRS) and neurologic toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), TECVAYLI^® and TALVEY^® are available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TECVAYLI^® and TALVEY^® REMS. Healthcare facilities that dispense and administer TECVAYLI^® and TALVEY^® must be enrolled and comply with the REMS requirements, including the healthcare professionals who prescribe, dispense, or administer TECVAYLI^® and TALVEY^®. These facilities and healthcare professionals should be trained about the management of CRS and neurologic toxicities, including ICANS.

Consult a TECVAYLI^® or TALVEY^® prescribing physician if you have an eligible patient

An eligible patient is assessed for treatment with TECVAYLI^® or TALVEY^® by the treating physician at a Certified Treatment Center in consultation with the patient's primary oncologist. TECVAYLI^® and/or TALVEY^® availability is not guaranteed at the locations listed.